Signature of Aberrantly Expressed microRNAs in the Striatum of Rotenone-Induced Parkinsonian Rats

Neurochem Res. 2018 Nov;43(11):2132-2140. doi: 10.1007/s11064-018-2638-0. Epub 2018 Sep 28.

Abstract

Parkinson's disease (PD) is a highly complex brain disorder regarding clinical presentation, pathogenesis, and therapeutics. The cardinal motor signs, i.e., rigidity, bradykinesia, and unilateral tremors, arise in consequence of a progressive neuron death during the prodromal phase. Although multiple transmission systems are involved in disease neurobiology, patients will cross the line between the prodromal and early stage of diagnosed PD when they had lost half of the dopaminergic nigrostriatal cells. As the neurons continue to die ascending the neuroaxis, patients will face a more disabling disease with motor and nonmotor signs. Shedding light on molecular mechanisms of neuron death is an urgent need for understanding PD pathogenesis and projecting therapeutics. This work examined the expression of microRNAs in the striatum of parkinsonian rats chronically exposed to rotenone (2.5 mg/Kg, i.p., daily for 10 days). Rotenone caused motor deficits, the loss of TH(+) cells in the nigrostriatal pathway, and a marked microgliosis. This parkinsonian rat striatum was examined at 26 days after the last rotenone injection, for quantification of microRNAs, miR-7, miR-34a, miR-26a, miR-132, miR-382, and Let7a, by qPCR. Parkinsonian rats presented a significant increase in miR-26a and miR-34a (1.5 and 2.2 fold, respectively, P < 0.05), while miR-7 (0.5 fold, P < 0.05) and Let7a were downregulated. This work reports for first time microRNAs aberrantly expressed in the striatum of rotenone-induced parkinsonian rats, suggesting that this dysregulation may contribute to PD pathogenesis. Beyond revealing new clues of neurodegeneration, our findings might prime further studies targeting miRNAs for neuroprotection or even for diagnosis proposal.

Keywords: Neurodegeneration; Parkinson’s disease; Rotenone; Striatum; miRNA.

MeSH terms

  • Animals
  • Corpus Striatum / drug effects
  • Corpus Striatum / metabolism*
  • Disease Models, Animal
  • Dopaminergic Neurons / metabolism*
  • Male
  • MicroRNAs / drug effects
  • MicroRNAs / metabolism*
  • Neostriatum / drug effects*
  • Neostriatum / metabolism
  • Neuroprotective Agents / pharmacology
  • Parkinson Disease / metabolism
  • Parkinsonian Disorders / metabolism
  • Rats, Wistar
  • Rotenone / pharmacology
  • Substantia Nigra / drug effects
  • Substantia Nigra / metabolism*

Substances

  • MicroRNAs
  • Neuroprotective Agents
  • Rotenone